A Phased Desensitization Protocol With Rituximab and Bortezomib for Highly Sensitized Kidney Transplant Candidates

Kentaro Ide, MD, PhD, Yuka Tanaka, PhD, Yu Sasaki, MS, Hiroyuki Tahara, MD, PhD, Masahiro Ohira, MD, PhD, Kohei Ishiyama, MD, PhD, Hirotaka Tashiro, MD, PhD, Hideki Ohdan, MD, PhD

Background. Desensitization protocols comprising plasmapheresis, IVIGs, and rituximab and/or bortezomib have allowed for successful kidney transplantation in some highly HLA-sensitized patients with end-stage renal disease. However, the optimal combination of these therapies and their proper timing remains entirely unknown. We propose a phased desensitization strategy using rituximab followed by bortezomib as a safer method. Methods. Three sensitized kidney transplant candidates who could not be desensitized using our conventional protocol, which consists of a single rituximab dose combined with plasmapheresis, were enrolled in this study. When IgM+ CD27− naive B cells reappeared but IgM+ CD27+ memory B cells remained undetectable in their peripheral blood, the patients were treated with 1 cycle of bortezomib followed by plasmapheresis. Results. After bortezomib treatment, patients’ donor-specific anti-HLA antibodies (DSA) values were decreased, and cross-match tests were consistently negative. All 3 patients underwent living donor kidney transplantation. They showed immediate renal function, and both DSA and non-DSA were undetectable during the observation period. Neither antibody-mediated rejection nor severe acute cellular rejection was encountered in these patients after transplantation. Conclusions. The present cases suggest that a phased use of rituximab and bortezomib can safely desensitize highly sensitized kidney transplant candidates.

Received 4 February 2015. Revision requested 15 April 2015. Accepted 4 May 2015.

Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. This research was supported by a Grant-in-Aid for Scientific Research (C) (26461911) from the Japan Society for the Promotion of Science. The study was registered in UMIN-CTR (University hospital Medical Information Network—Clinical Trials Registry): UMIN000011914.

The authors declare no conflicts of interest.

K.I. and H.O. participated in the research design, performance of the research, data analysis, and writing of the article. Y.T. and Y.S. participated in data analysis. H.T., M.O., K.I., and H.T. participated in the performance of the research.

Correspondence: Kentaro Ide, MD, and Hideki Ohdan, MD, Department of Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, 1-2-3 Kasumi Minami-ku, Hiroshima, 734-8551, Japan. (ideken@hiroshima-u.ac.jp, hohdan@hiroshima-u.ac.jp)

Supplemental digital content (SDC) is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal’s Web site (www.transplantjournal.com).

Copyright © 2015 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0/

ISSN: 2373-8731
DOI: 10.1097/TXD.0000000000000526

Copyright © 2015 The Authors. Transplantation Direct. Published by Wolters Kluwer Health, Inc.
may cause hypogammaglobulinemia, administering both agents with a time lag may be safer. Hence, we propose a phased desensitization strategy using rituximab followed by bortezomib for highly sensitized kidney transplant candidates (Figure 1).

**METHODS**

**Study Design and Desensitization Protocol**

This study was conducted with informed consent using a protocol approved by the institutional review board of the
B cells in the peripheral blood, they received 1 cycle of intervals. After verifying the absence of IgM+ CD27+ memory B cell subsets was determined at 3-month DFPP/low-IVIG sessions, underwent the phased desensitization protocol as follows; that is, they started 1 week before the DFPP/low-IVIG treatment. Three patients, in whom cross-match tests remained positive despite Tacrolimus (target trough level: 5-10 ng/mL) followed by low doses (100 mg/kg per day) of IVIG (DFPP/low-IVIG).10 Tacrolimus (target trough level: 5-10 ng/mL) followed by DFPP/low-IVIG. The kidney transplant candidates, who had positive T-cell flow cytometry cross-match (T-FCXM) or immunocomplex capture fluorescence analysis (ICFA) class I results, received our conventional desensitization protocol as follows; that is, they received a single dose of rituximab (375 mg/m²) combined with 3 double-filtration plasmapheresis (DFPP) sessions, followed by low doses (100 mg/kg per day) of IVIG (DFPP/low-IVIG).10 Tacrolimus (target trough level: 5-10 ng/mL) or cyclosporine A (target trough level: 80-100 ng/mL) and mycophenolate mofetil (MMF, 20 mg/kg per day) were started 1 week before the DFPP/low-IVIG treatment. Three patients, in whom cross-match tests remained positive despite 3 DFPP/low-IVIG sessions, underwent the phased desensitization protocol. In these patients, the proportion of peripheral blood B cell subsets was determined at 3-month intervals. After verifying the absence of IgM* CD27* memory B cells and the presence of CD19* IgM* CD27* naive mature B cells in the peripheral blood, they received 1 cycle of bortezomib (1.3 mg/m², days 1, 4, 8, and 11), as established in the treatment of multiple myeloma,11 followed by DFPP/low-IVIG. Dexamethasone 20 mg was added on the day of bortezomib administration as well as the following day.

B Cell Phenotype Analyses

For B cell phenotyping, peripheral blood mononuclear cells were stained with fluorescein isothiocyanate (FITC)-conjugated anti-IgM; phycoerythrin-conjugated anti-CD5, anti-CD19, anti-CD20, or anti-CD27; and allophycocyanin-conjugated anti-CD38 mAbs. For plasma cell identification, peripheral blood mononuclear cells were stained with fluorescein isothiocyanate–conjugated anti-IgM, phycoerythrin-conjugated anti-CD19, and allophycocyanin-conjugated anti-CD38 mAbs. Dead cells were excluded from the analysis by light-scatter and/or propidium iodide staining. Flow cytometric (FCM) analyses were performed on a FACSCalibur (BD Biosciences, Mountain View, CA).

Cross-Matching and Ab Detection

The complement-dependent cytotoxicity cross-match and the T-FCXM were performed as previously reported.10 As an alternative cross-match test, ICFA was performed according to the manufacturer’s protocol (WAKFlow HLA Ab class I&II, Wakunaga Pharmaceutical Co., Ltd., Japan). A screening test dedicated to detecting antibodies against HLA class I and class II in addition to MHC class I-related chain A was performed on a Luminex platform (LABScan 100 Flow Analyzer; Luminex Corporation, Austin, TX) using LABScreen Single Antigen assays (One Lambda). The results were recorded as mean fluorescence intensity. Mean fluorescence intensity values greater than 1000 were considered positive. Calculated panel reactive antibodies (CPRA) were computed using the United Network for Organ Sharing’s CPRA calculator to evaluate the extent of a recipient’s sensitization. The antibody type isoagglutinin titer for IgM and IgG were serially measured as previously reported.12

Immune Monitoring

To evaluate the immune reactivity of these patients, we evaluated the antidonor T-cell response by performing mixed lymphocyte reactions (MLR) assay with the intracellular carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeling technique (CFSE-MLR assay). The CFSE-MLR assay allows the quantification of cell proliferation, which is a response to allogeneic stimuli, and the simultaneous determination of the phenotype of the proliferating cells by using multiparameter FCM. CD4* and CD8* T-cell proliferations and stimulation indexes were quantified by using a previously reported method.10

RESULTS

Patient Characteristics

Consistent with the enrollment criteria, all the 3 patients had positive T-FCXM and ICFA class I test results before desensitization (Table 1A). In fact, in 2 of the 3 patients, the results were strongly positive for T-cell complement-dependent cytotoxicity cross-match (81-100% lysed cells), and both patients were ABO-incompatible living donor kidney transplant candidates. These 2 patients had previously received a living donor kidney transplant, but did not undergo an allograft nephrectomy before retransplantation.

Desensitization Outcomes

In accordance with the concept of this study, after rituximab treatment, we waited for the recovery of naive mature B cells in the peripheral blood. The recovery of mature B cells was defined as the presence of more than 1% of IgM* CD19* B cells among the peripheral blood lymphocytes (to ensure statistical significance, data on 30,000 lymphocytes were collected for each sample). Even after the reappearance of IgM* CD19* B cells, IgM* CD27* memory B cells remained undetectable in the peripheral blood of all patients until kidney

### TABLE 1A: Baseline Characteristics

| Parameters                     | Patient 1 | Patient 2 | Patient 3 |
|--------------------------------|-----------|-----------|-----------|
| Age, y                         | 58        | 61        | 24        |
| Sex                            | Male      | Female    | Male      |
| Original kidney disease        | Glomerulonephritis | Diabetic nephropathy | Glomerulonephritis |
| Sensitizing event              | Previous transplant | Pregnancy | Previous transplant |
| Living donor relationship      | Wife      | Husband   | Father    |
| Donor age, y                   | 56        | 63        | 58        |
| HLA mismatches                 | Full mismatch | Full mismatch | One haplotyping identical |
| ABO compatibility              | Incompatible | Identical | Incompatible |
| T-FCXM                         | Positive  | Negative  | Positive  |
| ICFA-I                         | Positive  | Positive  | Positive  |
| ICFA-II                        | Negative  | Negative  | Negative  |
| Luminex SA test result         |            |            |            |
| SA reactivities to HLA class I | 11        | 16        | 7         |
| SA reactivities to HLA class II| 6         | 0         | 7         |
| Donor-specific alloantibody    |            |            |            |
| (MFI)                          | (18694.12) | (11110.51) | (20763.28) |

T-FCXM, T-cell complement-dependent cytotoxicity cross-match; ICFA-I, ICFA class I; ICFA-II, ICFA class II; SA, single antigen; MFI, mean fluorescence intensity.
The mean time interval between rituximab treatment and bortezomib initiation was 13.7 months (Table 1B). Both drugs were tolerated well with no adverse events. After bortezomib administration followed by 3 DFPP/low-IVIG sessions, patients’ DSA values and CPRA were decreased (Figure 2) and cross-match tests including the FCM and ICFA were consistently negative (Table 1B).

We previously reported that a subset of CD19+ IgM+ CD5+ B-1 cells exclusively responds to blood group A carbohydrate antigens, and these cells need to be depleted in advance to successfully accomplish adult ABO-incompatible organ transplantation.13,14 After rituximab/bortezomib/PP, the DSA values of all 3 patients were decreased and cross-match test results, including the FCM and ICFA, were consistently negative (Table 1B). Because the IgM+ CD19+ B cells that reappeared after rituximab treatment contained IgM+ CD5+ B-1 cells, 2 candidates for ABO-incompatible kidney transplantation additionally received a single dose of rituximab.

**TABLE 1B. Desensitization and Posttransplant Outcomes**

| Parameters                      | Patient 1 | Patient 2 | Patient 3 |
|---------------------------------|-----------|-----------|-----------|
| Duration between RIT and BTZ treatment, mo | 20        | 9         | 12        |
| Percentage of naïve B cells in PBMCs at BTZ, % | 8.3       | 1.0       | 1.9       |
| ICA-I (index)                   |           |           |           |
| Predisensitization              | 116       | 6.8       | 8.1       |
| Postdesensitization             | 1.9       | 1.1       | 1.1       |
| Immunosuppressant               | TAC       | CsA       | TAC       |
| Posttransplant follow up, mo    | 48        | 28        | 18        |
| eGFR at latest follow-up, mL/min per 1.73 m² | 57.0      | 51.0      | 55.0      |

The eGFR of each participant was calculated based on age and serum creatinine value (S-Cr) according to the new Japanese equation as follows: eGFR (mL/min per 1.73 m²) = 194 × Age-0.287 × S-Cr-1.094 (if female × 0.739).

RIT, rituximab; BTZ, bortezomib; PBMC, peripheral blood mononuclear cell; eGFR, estimated glomerular filtration rate; CsA, cyclosporine A.

**FIGURE 2.** Kinetics of preexisting DSA and CPRA. The CPRA were computed using UNOS’ CPRA calculator to evaluate the extent of a recipient’s sensitization. After transplantation, each patients’ DSA (specific for HLA-A2 in patient 1; HLA-B7 in patient 2; and HLA-B52 in patient 3) and CPRA were undetectable. Each line represents a single patient. Blue lines, patient 1; orange lines, patient 2; and green lines, patient 3.
(375 mg/m²) 2 weeks before transplantation, despite negative cross-match test results. The interval between the final administration of bortezomib and the second administration of rituximab in these 2 patients was 19 weeks and 10 weeks, respectively. These time lags were determined by verifying the replenishment of CD19+ CD38+ plasma cells in patients’ peripheral blood (data not shown). The kinetics of anti-A Ab titers are shown in Figure S2, http://links.lww.com/TXD/A2. No infectious episodes were encountered during desensitization in all patients.

Posttransplantation Outcomes
The induction immunosuppression protocol comprised tacrolimus or cyclosporine A, MMF, and methylprednisolone, but did not include basiliximab (Table 1B). The doses of the 3 agents were comparable to those used in nonsensitized cases. Patients displayed immediate renal function, and DSA was persistently undetectable after transplantation (Table 1B). At 48, 28, and 18 months into their follow-up, respectively, the patients are entirely healthy. Serum creatinine values were 1.04, 0.96, and 1.36 mg/dL, respectively, at the latest follow-up and renal allograft biopsies conducted within 1 year demonstrated no evidence of rejection, microvascular inflammation, or allograft glomerulonephritis. The Ab titers specific for cytomegalovirus and varicella zoster virus remained above the level of protection during the observation period (Figure S3, SDC, http://links.lww.com/TXD/A2), whereas both DSA and non-DSA were undetectable even at the latest follow-up (Table 1B and Figure S4, SDC, http://links.lww.com/TXD/A2).

**DISCUSSION**

To date, several aggressive protocols have been developed to eliminate Abs against allogeneic HLAs in patients with a positive cross-match. Mounting evidence indicates that high-dose IVIG has a limited ability to reduce HLA Abs, but a few centers reported success with high-dose IVIG plus rituximab. However, the overall experience in multiple centers has shown high antibody-mediated rejection rates, particularly in patients with the highest degrees of HLA sensitization. Recent experiences with plasma cell-targeted therapies based on bortezomib in addition to rituximab are relatively small in number but may represent an important alternative to nondeletional strategies using IVIG.

There have been reports of patients with persistent B-cell dysfunction even after the completion of rituximab treatment for B-cell lymphomas and autoimmune conditions, although the incidence is rare. To avoid either persistent immune dysfunction or hypogammaglobulinemia, identifying immune recovery via periodic monitoring is prudent before starting additional immunomodulatory therapy with bortezomib. It has been reported that mature B cells recover more rapidly, returning to baseline by 6 months, whereas memory B cells remain low at 2 years after rituximab treatment. Hence, the period after rituximab treatment characterized by the presence of mature B cells but the absence of memory B cells may represent an appropriate therapeutic window for the subsequent bortezomib treatment (Figure 1). The reappeared mature B cells may promptly replenish plasma cells producing immunoglobulin without specificity for HLA even after the bortezomib-induced destruction of preexisting plasma cells, possibly leading to a competent immune-defensive activity. Consistent with the previous observation, IgM+ CD27+ memory B cells remained undetectable in the peripheral blood during observation even after the reappearance of IgM+ CD19+ B cells (Figure S1, SDC, http://links.lww.com/TXD/A2). Because it is entirely unknown whether B lymphopoiesis in the peripheral blood reflects B lymphopoiesis in secondary lymphoid tissues, such as the spleen and lymph nodes, the validity of this provisional definition of B cell recovery remains to be elucidated in future studies.

Alloantigen-reactive T cells are thought to play a key role in the production of DSA. In this study, we evaluated the antidonor T-cell response by using CFSE-MLR assay. Owing to the continuous administration of CNI and MMF during desensitization, the antidonor T-cell responses in all the 3 patients were decreased in the CFSE-MLR assay compared with those before desensitization (Figure S5, SDC, http://links.lww.com/TXD/A2). The effective suppression of alloantigen-reactive T cells might be a prerequisite for successful desensitization for highly sensitized cases. If all-reactive T cells (probably memory T cells) are still in the activated state when B cells reappear after rituximab treatment, the newly formed B cells are possibly resensitized. Hence, our phased desensitization protocol with rituximab and bortezomib might be effective in cases with well-suppressed T-cell responses. To address this speculation, future studies are needed.

One of the striking findings in this series might be the minimal impact of the phased desensitization protocol on Abs specific for varicella zoster virus and cytomegalovirus (Figure S3, SDC, http://links.lww.com/TXD/A2) despite its remarkable depleting effects on both DSA and non-DSA. Such a differential ability of proteasome inhibition to affect DSA and not Abs against viruses may be due to individual plasma cell activity. It is likely that bortezomib will have a differential effect on plasma cells that produce high amounts of anti-HLA Abs compared with those that produce low amounts of Abs specific for various viruses. Apart from such a speculative mechanism, other unknown mechanisms may also exist.

Although cross-match test results were consistently negative in this series, 2 recipients of kidney allografts from ABO-incompatible donors received additional rituximab treatment because the reappeared IgM+ CD19+ B cells contained IgM+ CD5+ B-1 cells, which potentially respond to blood group A/B antigens. However, the necessity of this additional treatment remains to be elucidated, as it is unknown whether those newly formed IgM+ CD5+ CD27+ B-1 cells are already equipped with the specificity for A/B antigens.

In conclusion, the present cases suggest that a phased use of rituximab and bortezomib can safely desensitize highly HLA-sensitized kidney transplant candidates, warranting a further larger scale prospective study.

**ACKNOWLEDGMENTS**

The authors thank Kiyokawa M, Ishida Y, Hiraoka T, Kurita E, Kono M, and Igarashi Y for technical assistance. This work was carried out at the Natural Science Center for Basic Research and Development, Hiroshima University.

**REFERENCES**

1. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735–739.
2. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant. 2002;2:755–760.
3. Jordan SC, Tyen D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. *J Am Soc Nephrol*. 2004;15:3256–3262.

4. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics. *Transplantation*. 2004;77:542–548.

5. Kure VB, Vanikar AV, Trivedi HL, et al. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience. *Saudi J Kidney Dis Transpl*. 2011;22:662–669.

6. Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody-Hum Antibod. 2004;13:55–62.

7. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. *Arthritis Res Ther*. 2009;11:R123.

8. Tiburzy B, Kulkarni U, Hauser AE, et al. Plasma cells in immunopathology: concepts and therapeutic strategies. *Semin Immunopathol*. 2014;36:277–288.

9. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. *Nat Med*. 2006;14:748–755.

10. Tanimine N, Ide K, Yamashita M, et al. Kinetics of cellular and humoral immunity in a successful case of positive crossmatch kidney transplantation: a case report. *Transplant Proc*. 2011;43:2411–2414.

11. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. *Haematologica*. 2006;91:929–934.

12. Kobayashi T, Saito K. A series of surveys on assay for anti-A/B antibody by Japanese ABO-Incompatible Transplantation Committee. *Xenotransplantation*. 2006;13:136–140.

13. Zhou W, Ohdan H, Asahara T. Calcineurin inhibitors block B-1 cell differentiation: the relevance to immunosuppressive treatment in ABO-incompatible transplantation. *Transplant Proc*. 2005;37:1808–1811.

14. Irie T, Ohdan H, Zhou W, et al. The persistent elimination of B cells responding to blood group A carbohydrates by synthetic group A carbohydrates and B-1 cell differentiation blockade: novel concept in preventing antibody-mediated rejection in ABO-incompatible transplantation. *Blood*. 2007;110:4567–4575.

15. Stegall MD, Gloor J, Winters JL, et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. *Am J Transplant*. 2006;6:346–351.

16. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. *N Engl J Med*. 2008;359:242–251.

17. Abu Jawdeh BG, Cuffy MC, Alloway RR, et al. Desensitization in kidney transplantation: review and future perspectives. *Clin Transplant*. 2014;28:494–507.

18. Raghavan R, Jeroudi A, Achkar K, et al. Bortezomib in kidney transplant desensitization: a case report. *Clin Transpl*. 2009:339–342.

19. Kaplan B, Kopyltsova Y, Khokhar A, et al. Rituximab and immune deficiency: case series and review of the literature. *J Allergy Clin Immunol Pract*. 2014;2:594–600.

20. Ichii M, Critani K, Kanakura Y. Early B lymphocyte development: similarities and differences in human and mouse. *World J Stem Cells*. 2014;6:421–431.